UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial

British journal of dermatology (1951), 2014-11, Vol.171 (5), p.1215-1219

2014

Volltextzugriff (PDF)

Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink

Journal of the European Academy of Dermatology and Venereology, 2015-05, Vol.29 (5), p.955-963

2015

Volltextzugriff (PDF)

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

Journal of the European Academy of Dermatology and Venereology, 2016-05, Vol.30 (5), p.864-865

2016

Volltextzugriff (PDF)

Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor

Journal of drugs in dermatology, 2016-02, Vol.15 (2), p.183

2016

Volltextzugriff (PDF)

615 Meaningful change in children’s dermatology life quality index (DLQI) and lesion counts in patients with molluscum contagiosum

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S105-S105

2023

Volltextzugriff (PDF)

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative

JAMA dermatology (Chicago, Ill.), 2022-12, Vol.158 (12), p.1429

2022

Volltextzugriff (PDF)

294 Berdazimer 10.3% gel, a nitric oxide-releasing topical medication for molluscum contagiosum, triggers BOTE (Beginning Of The End) inflammation and accelerates resolution

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S50

2022

Volltextzugriff (PDF)

LB940 SB206 (berdazimer gel 10.3%) for the treatment of molluscum contagiosum: results from a Japanese Phase 2 Study (SKN15B01)

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S164-S164

2024

Volltextzugriff (PDF)

1131 Antiviral effect of berdazimer sodium on molluscum contagiosum virus: Potential implications for clinical observations of lesion resolution

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S194-S194

2023

Volltextzugriff (PDF)

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

Ophthalmology (Rochester, Minn.), 2011-06, Vol.118 (6), p.1107-1118

2011

Volltextzugriff (PDF)

400 BOTE (Beginning Of The End) inflammation can be enhanced with SB206, a nitric oxide-releasing topical medication for molluscum contagiosum

Journal of investigative dermatology, 2021-05, Vol.141 (5), p.S70

2021

Volltextzugriff (PDF)

586 Topical nitric oxide releasing therapy with 2% SB414 cream downregulated major gene expressions in patients with atopic dermatitis

Journal of investigative dermatology, 2019-05, Vol.139 (5), p.S101-S101

2019

Volltextzugriff (PDF)

LB1096 Results of phase 2 study evaluating the efficacy and safety of SB206, topical berdazimer sodium gel, in subjects with Molluscum Contagiosum

Journal of investigative dermatology, 2019-09, Vol.139 (9), p.B14-B14

2019

Volltextzugriff (PDF)

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

Investigative ophthalmology & visual science, 2011-09, Vol.52 (10), p.7498-7505

2011

Volltextzugriff (PDF)

1306 Topical nitric oxide releasing therapy with SB208 increased fingernail growth

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S222-S222

2018

Volltextzugriff (PDF)

543 An evaluator blinded study to evaluate the cumulative irritation potential of topically-applied GSK2894512 cream in healthy subjects

Journal of investigative dermatology, 2016-05, Vol.136 (5), p.S96-S96

2016

Volltextzugriff (PDF)

Une réduction du PAS ≥ 90 % est associée à une amélioration de la qualité de vie et du prurit : résultats d’une étude de phase 2 chez des patients atteints de psoriasis en plaque modéré à sévère, traités par ixekizumab

Annales de dermatologie et de vénéréologie, 2013-12, Vol.140 (12), p.S504-S505

2013

Volltextzugriff (PDF)

A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis

Journal of the American Academy of Dermatology, 2019-01, Vol.80 (1), p.89-98.e3

2019

Volltextzugriff (PDF)

Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

Journal of the American Academy of Dermatology, 2019-03, Vol.80 (3), p.714-721

2019

Volltextzugriff (PDF)

Defining clinically meaningful improvement in molluscum contagiosum

Journal of the American Academy of Dermatology, 2024-02, Vol.90 (2), p.443-445

2024

Volltextzugriff (PDF)

Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis

Pediatric dermatology, 2024-05, Vol.41 (3), p.438-444

2024

Volltextzugriff (PDF)

The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology

Viruses, 2023-11, Vol.15 (12), p.2360

2023

Volltextzugriff (PDF)

Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study

Clinical pharmacology in drug development, 2018-06, Vol.7 (5), p.524-531

2018

Volltextzugriff (PDF)

SB206, a Nitric Oxide–Releasing Topical Medication, Induces the Beginning of the End Sign and Molluscum Clearance

JID innovations, 2021-09, Vol.1 (3), p.100019-100019, Article 100019

2021

Volltextzugriff (PDF)

Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study

Ophthalmology (Rochester, Minn.), 2011-10, Vol.118 (10), p.2014-2021

2011

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(40)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial

Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor

615 Meaningful change in children’s dermatology life quality index (DLQI) and lesion counts in patients with molluscum contagiosum

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative

294 Berdazimer 10.3% gel, a nitric oxide-releasing topical medication for molluscum contagiosum, triggers BOTE (Beginning Of The End) inflammation and accelerates resolution

LB940 SB206 (berdazimer gel 10.3%) for the treatment of molluscum contagiosum: results from a Japanese Phase 2 Study (SKN15B01)

1131 Antiviral effect of berdazimer sodium on molluscum contagiosum virus: Potential implications for clinical observations of lesion resolution

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

400 BOTE (Beginning Of The End) inflammation can be enhanced with SB206, a nitric oxide-releasing topical medication for molluscum contagiosum

586 Topical nitric oxide releasing therapy with 2% SB414 cream downregulated major gene expressions in patients with atopic dermatitis

LB1096 Results of phase 2 study evaluating the efficacy and safety of SB206, topical berdazimer sodium gel, in subjects with Molluscum Contagiosum

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

1306 Topical nitric oxide releasing therapy with SB208 increased fingernail growth

543 An evaluator blinded study to evaluate the cumulative irritation potential of topically-applied GSK2894512 cream in healthy subjects

Une réduction du PAS ≥ 90 % est associée à une amélioration de la qualité de vie et du prurit : résultats d’une étude de phase 2 chez des patients atteints de psoriasis en plaque modéré à sévère, traités par ixekizumab

A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis

Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

Defining clinically meaningful improvement in molluscum contagiosum

Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis

The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology

Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study

SB206, a Nitric Oxide–Releasing Topical Medication, Induces the Beginning of the End Sign and Molluscum Clearance

Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study

Suchergebnisse filtern